Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Steven Paul Insider Profile
11 Followers
Steven Paul, Director at SAGE Therapeutics, holds 593.11K shares in SAGE Therapeutics (Ticker: SAGE), holds ― shares in Voyager Therapeutics (Ticker: VYGR), holds 0.00 shares in Karuna Therapeutics (Ticker: KRTX).
Profitable Transactions
4 out of 5 Profitable Transactions
Average Return
+130.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Steven Paul holds in companies
Most Profitable Insider Trade
Stock:
Karuna Therapeutics
(KRTX)
(KRTX)
Rating:Informative Buy
Date:Jul 01, 2019 - Jul 01, 2020
Return:+406.90%
The most profitable trade made by Steven Paul
Steven Paul's Trading History
SAGE Therapeutics
Nov 30, 2022
Director
Uninformative Buy
190.80
$3.33M
Voyager Therapeutics
―
Director
―
―
Karuna Therapeutics
Mar 18, 2024
―
Uninformative Sell
49.82M
$0.00
Alnylam Pharma
Apr 05, 2022
Director
Uninformative Buy
169.95K
$245.44K
Sigma-Aldrich Corp
Nov 19, 2015
―
Uninformative Sell
66.92K
―
Eli Lilly & Co
Feb 03, 2010
EVP, Science and Technology
Uninformative Buy
610.79K
$59.84M
List of latest transactions for each holding click on a transaction to see Steven Paul's performance on stock
You May Also Like
Steven Paul insider profile FAQ
What is the percentage of profitable transactions made by Steven Paul?
The percentage of profitable transactions made by Steven Paul is 80%.
What is the average return per transaction made by Steven Paul?
The average return per transaction made by Steven Paul is 130.60%.
What stocks does Steven Paul hold?
Steven Paul holds: SAGE, VYGR, KRTX, ALNY, SIAL, LLY stocks.
What was Steven Paul’s latest transaction?
Steven Paul latest transaction was an Uninformative Buy of $190.80.
What was Steven Paul's most profitable transaction?
Steven Paul’s most profitable transaction was an Informative Buy of KRTX stock on July 1, 2019. The return on the trade was 406.90%.
What is Steven Paul's role in SAGE Therapeutics?
Steven Paul's role in SAGE Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.